Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan
S. Hisata (Tochigi, Japan), M. Bando (Tochigi, Japan), S. Homma (Tokyo, Japan), K. Kataoka (Aichi, Japan), T. Ogura (Kanagawa, Japan), S. Izumi (Tokyo, Japan), S. Sakamoto (Tokyo, Japan), Y. Saito (Tokyo, Japan), K. Watanabe (Kyoto, Japan), Y. Shimizu (Tochigi, Japan), M. Kato (Tokyo, Japan), N. Inase (Tokyo, Japan)
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Related content which might interest you: